论文部分内容阅读
目的探讨肺癌患者化疗期间发生化疗相关性白细胞减少(CIL)的危险因素。方法采用病例对照研究的方法,回顾性收集2012年1月至2014年12月间收治的138例肺癌化疗患者,按CIL发生情况分为实验组(发生CIL)和对照组(未发生CIL),实验组90例,对照组48例。对两组患者的临床相关指标进行单因素和多因素分析。结果 138例肺癌化疗患者中,90例患者出现CIL,发生率为65.2%。两组患者的性别(P=0.437)、年龄(P=0.103)、基础疾病(P=0.176)差异无统计学意义。单因素分析显示,实验组患者的肝功能异常、治疗前白细胞降低、化疗药物相对剂量强度、肺癌分期、化疗次数与对照组差异有统计学意义(P<0.05)。多因素分析显示,治疗前白细胞减低(OR=3.494)、肺癌分期(OR=6.345)、化疗次数≥4次(OR=18.247)是发生CIL的危险因素。结论治疗前白细胞降低、肺癌分期、化疗次数≥4次是肺癌化疗患者发生CIL的危险因素。
Objective To investigate the risk factors of chemotherapy-associated leukopenia (CIL) during chemotherapy in patients with lung cancer. Methods A case-control study was conducted to retrospectively collect 138 cases of lung cancer who underwent chemotherapy from January 2012 to December 2014. The patients were divided into experimental group (CIL) and control group (CIL did not occur) according to the occurrence of CIL, 90 cases in the experimental group and 48 cases in the control group. Univariate and multivariate analyzes were performed on clinically relevant indicators in both groups. Results Among the 138 patients with chemotherapy of lung cancer, CIL was found in 90 patients, the incidence was 65.2%. There was no significant difference in gender (P = 0.437), age (P = 0.103), and underlying disease (P = 0.176) between the two groups. Univariate analysis showed that patients in the experimental group had abnormal liver function, leukopenia before treatment, relative dose intensity of chemotherapy drugs, stage of lung cancer, the number of chemotherapy and the control group (P <0.05). Multivariate analysis showed that pre-treatment leukopenia (OR = 3.494), stage of lung cancer (OR = 6.345) and chemotherapy ≥4 (OR = 18.247) were risk factors for CIL. Conclusions Pretreatment leukopenia, lung cancer staging, chemotherapy ≥ 4 times is a risk factor for CIL in patients with lung cancer chemotherapy.